TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23551622

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once a day (OaD)
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Tadalafil on demand (PRN)
Number of subjects: 770

Group type: COMPARATOR
Intervention: Sildenafil on demand (PRN)
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Tadalafil OaD
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Tadalafil PRN
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 770
Study: 20074337

Group type: EXPERIMENTAL
Intervention: Evidence-based patient information (EBPI) about subthreshold elevated blood glucose levels and diabetes primary prevention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information about elevated blood glucose levels and diabetes primary prevention available on the internet
Number of subjects: 0
Study: 18194307

Group type: EXPERIMENTAL
Intervention: Treatment with bypassing agents (FEIBA and NovoSeven)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Treatment with one bypassing agent (effective)
Number of subjects: 48
Study: 17165494

Group type: EXPERIMENTAL
Intervention: Acupuncture plus antiasthma agents
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (antiasthma agents only)
Number of subjects: 104
Study: 14592997

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10516117

Group type: EXPERIMENTAL
Intervention: Early group (15 min after surgery)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Late group (49 min after surgery)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Early group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Late group
Number of subjects: 16
Study: 7752754

Group type: EXPERIMENTAL
Intervention: Vitamin A (100,000 IU)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study: 2042789

Group type: EXPERIMENTAL
Intervention: Desmopressin 0.3 micrograms.kg‐1, infused over 15 min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7015989

Group type: EXPERIMENTAL
Intervention: Cimetidine 0.8 g/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Glycopyrrolate 4 mg/day
Number of subjects: 26
Study: 30073290

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily for 8 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 200
Study: 28376440

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 834
Study: 25687957

Group type: EXPERIMENTAL
Intervention: Robotic Training (RT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional Training (CT)
Number of subjects: 40
Study: 23715049

Group type: EXPERIMENTAL
Intervention: CNI withdrawal
Number of subjects: 119

Group type: COMPARATOR
Intervention: MMF withdrawal
Number of subjects: 119
Study: 20533634

Group type: COMPARATOR
Intervention: Clearfil SE Bond, no contamination (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond, contamination group 1 (CG1): primer application/ contamination/primer re‐application
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond, contamination group 2 (CG2): primer application/contamination/wash/dry/primer re‐application
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond, contamination group 3 (CG3): primer application/adhesive application/light curing/contamination/ adhesive re‐application/light curing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond, contamination group 4 (CG4): primer application/adhesive application/light curing/contamination/wash/dry/adhesive re‐application/light curing
Number of subjects: 60

Group type: COMPARATOR
Intervention: AdheSE, no contamination (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AdheSE, contamination group 1 (CG1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AdheSE, contamination group 2 (CG2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AdheSE, contamination group 3 (CG3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AdheSE, contamination group 4 (CG4)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tyrian SPE, no contamination (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tyrian SPE, contamination group 1 (CG1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tyrian SPE, contamination group 2 (CG2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tyrian SPE, contamination group 3 (CG3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tyrian SPE, contamination group 4 (CG4)
Number of subjects: 60
Study: 18262146

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (no pentoxifylline)
Number of subjects: 47
Study: 16606645

Group type: EXPERIMENTAL
Intervention: Single DMARD treatment with or without prednisolone (single group)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Combination DMARD treatment with prednisolone (combination group)
Number of subjects: 169
Study: 12950963

Group type: EXPERIMENTAL
Intervention: Molecular Adsorbents Recirculating System (MARS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 23
Study: 10385132

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) 40 mg, three times daily orally for 2 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 8598702

Group type: COMPARATOR
Intervention: Trials published in English
Number of subjects: 229

Group type: COMPARATOR
Intervention: Trials published in other languages
Number of subjects: 229

Group type: COMPARATOR
Intervention: Other-language trials
Number of subjects: 229
Study: 1760831

Group type: EXPERIMENTAL
Intervention: 50 mg sustained-release IS-5-MN
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 80 mg sustained-release IS-5-MN
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both dosages
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Elantan Long (50 mg sustained-release IS-5-MN)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 6760653

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 100 mg twice daily for 12 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 21
Study: 2932485

Group type: EXPERIMENTAL
Intervention: nomifensine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: amitriptyline
Number of subjects: 42

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study: 29958455

Group type: EXPERIMENTAL
Intervention: Low Glycaemic Index Diet (LGID)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Low Glycaemic Index Mediterranean Diet (LGIMD)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (without MetS)
Number of subjects: 163
Study: 26400923

Group type: EXPERIMENTAL
Intervention: active intermittent theta burst stimulation (iTBS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 19
Study: 24439984

Group type: EXPERIMENTAL
Intervention: Trandolapril 22 mg daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 22001561

Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Facilitated tucking
Number of subjects: 34

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 34
Study: 20052606

Group type: EXPERIMENTAL
Intervention: Holding a 1‐m saltwater crocodile before playing the EGM
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (playing EGM prior to holding the crocodile)
Number of subjects: 103
Study: 19323355

Group type: EXPERIMENTAL
Intervention: Linear frequency transposition with 30 minutes of training
Number of subjects: 9

Group type: COMPARATOR
Intervention: Conventional amplification
Number of subjects: 9
Study: 16873938

Group type: EXPERIMENTAL
Intervention: CoQ(10) supplementation (100 mg tid for 4 weeks)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CoQ(10) supplementation
Number of subjects: 21
Study: 12424684

Group type: EXPERIMENTAL
Intervention: Cefixime (2 mg/kg bodyweight)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nitrofurantoin
Number of subjects: 60
Study: 10939029

Group type: EXPERIMENTAL
Intervention: Policosanol (10 mg/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Lovastatin (20 mg/day)
Number of subjects: 53
Study: 7562758

Group type: EXPERIMENTAL
Intervention: Modified Rodnan skin thickness score (0-3 scale)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Reduced number of sites (5 sites: forearms, lower legs, anterior chest, upper arms, fingers)
Number of subjects: 8
Study: 2187941

Group type: EXPERIMENTAL
Intervention: Partial inferior turbinectomy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Laser turbinectomy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Turbinoplasty
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cryoturbinectomy
Number of subjects: 80
Study: 7033945

Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclopenthiazide
Number of subjects: 0
Study: 31916906

Group type: EXPERIMENTAL
Intervention: Educational leaflet regarding HPV vaccination and a second leaflet recommending discussion with husbands (Group A)
Number of subjects: 1499

Group type: COMPARATOR
Intervention: Educational leaflet regarding HPV vaccination only (Group B)
Number of subjects: 1499

Group type: COMPARATOR
Intervention: No leaflets (Group C)
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Group A (Educational leaflet + husband discussion)
Number of subjects: 1499

Group type: COMPARATOR
Intervention: Group B (Educational leaflet only)
Number of subjects: 1499

Group type: COMPARATOR
Intervention: Group C (No leaflets)
Number of subjects: 1499
Study: 30726689

Group type: EXPERIMENTAL
Intervention: Omadacycline (100 mg IV every 12 hours for two doses, then 100 mg IV every 24 hours; transition to oral 300 mg every 24 hours after 3 days allowed)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Linezolid (600 mg IV every 12 hours; transition to oral 600 mg every 12 hours after 3 days allowed)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Omadacycline
Number of subjects: 627

Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 627
Study: 29856291

Group type: EXPERIMENTAL
Intervention: Octreotide used when other therapies failed; previously prescribed octreotide for this clinical indication.
Number of subjects: 106

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Older age (clinician age 50-59 years).
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Lower proportions of people treated with octreotide (0%-20%).
Number of subjects: 106
Study: 26563147

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing/Cognitive Behavioral Therapy (MI-CBT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: MI-CBT (after crossover from TAU)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: MI-CBT
Number of subjects: 81
Study: 24828790

Group type: EXPERIMENTAL
Intervention: Early angioplasty
Number of subjects: 266

Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 266
Study: 23127770

Group type: EXPERIMENTAL
Intervention: 6 months i.m. leuprorelin prior to radiotherapy followed by 12 months i.m. leuprorelin and 18 months i.v. zoledronic acid (Z)
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: High dose rate brachytherapy (HDRB) boost
Number of subjects: 1071

Group type: COMPARATOR
Intervention: Adjuvant androgen suppression, bisphosphonates, and increasing EBRT dose
Number of subjects: 1071
Study: 20927698

Group type: EXPERIMENTAL
Intervention: Zonisamide (400-600 mg/day tapering to 100-300 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diazepam (130-50 mg/day tapering to 5-15 mg/day)
Number of subjects: 40
Study: 18372685

Group type: EXPERIMENTAL
Intervention: Daily exposure to a +Gz acceleration gradient
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring tools used during centrifuge spin
Number of subjects: 0
Study: 15791505

Group type: EXPERIMENTAL
Intervention: Fluoroquinolone prophylaxis (levofloxacin)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Discontinuation of fluoroquinolone prophylaxis
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fluoroquinolone prophylaxis (levofloxacin) reintroduced
Number of subjects: 9
Study: 11040765

Group type: EXPERIMENTAL
Intervention: Cross-cut teat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard single-hole teat
Number of subjects: 0
Study: 9069060

Group type: EXPERIMENTAL
Intervention: Dexamethasone therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 15
Study: 8325405

Group type: EXPERIMENTAL
Intervention: Suture removal at 12 weeks
Number of subjects: 135

Group type: COMPARATOR
Intervention: Suture removal at 6 or 9 weeks
Number of subjects: 135
Study: 3016764

Group type: EXPERIMENTAL
Intervention: Smoking two marijuana cigarettes (2.8% THC)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Smoking one marijuana cigarette and one placebo cigarette
Number of subjects: 4

Group type: COMPARATOR
Intervention: Smoking two placebo cigarettes
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Subjective effects measures (Addiction Research Center Inventory, Single Dose Questionnaire, Visual Analog Scale)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Psychomotor performance task
Number of subjects: 4
Study: 29308549

Group type: EXPERIMENTAL
Intervention: Individual Coping Power (ICP)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Group Coping Power (GCP)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Both ICP and GCP
Number of subjects: 360
Study: 28028674

Group type: EXPERIMENTAL
Intervention: MacVL with real-time feedback
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MacVL with real-time feedback plus video recordings
Number of subjects: 60

Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups tested using Macintosh direct laryngoscope
Number of subjects: 60
Study: 26002761

Group type: EXPERIMENTAL
Intervention: Rotigotine (dopamine agonist patch with 24-hour action)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 23090292

Group type: EXPERIMENTAL
Intervention: NaHCO(3) and CHO (B-CHO)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: NaHCO(3) (B-P)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo and CHO (P-CHO)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo and an artificial sweetener (P-P)
Number of subjects: 6
Study: 21572315

Group type: EXPERIMENTAL
Intervention: Mouth-to-nose breathing (MNB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mouth-to-mouth breathing (MMB)
Number of subjects: 20
Study: 20079321

Group type: EXPERIMENTAL
Intervention: 40 mg adalimumab
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: 80 mg adalimumab
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 302
Study: 16979327

Group type: EXPERIMENTAL
Intervention: Crocus sativus (petal) 30 mg/day (BD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (BD)
Number of subjects: 40
Study: 15580395

Group type: EXPERIMENTAL
Intervention: 5 million i.u. recombinant interferon alpha-2b (IFNA) administered s.c. in fasted state
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 5 million i.u. recombinant interferon alpha-2b (IFNA) administered s.c. after semiliquid test meal
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo administered s.c. in fasted state
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo administered s.c. after semiliquid test meal
Number of subjects: 25
Study: 11245552

Group type: EXPERIMENTAL
Intervention: Desogestrel-containing oral contraceptive (DSG-OC)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 9313879

Group type: COMPARATOR
Intervention: AML patients
Number of subjects: 26

Group type: COMPARATOR
Intervention: AML stromal layers
Number of subjects: 26
Study: 8359179

Group type: EXPERIMENTAL
Intervention: Quinidine (250 mg bisulfate) co-administration with Haloperidol (5 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Quinidine (250 mg bisulfate) co-administration with Reduced Haloperidol (5 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Quinidine (250 mg bisulfate) co-administration
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Haloperidol (5 mg) and Reduced Haloperidol (5 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Haloperidol (5 mg)
Number of subjects: 13
Study: 3521427

Group type: EXPERIMENTAL
Intervention: T-cell-depleted bone marrow (using monoclonal anti-T-cell antibody CT-2 and complement)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (non-T-cell-depleted bone marrow)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: T-cell-depleted bone marrow
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Infections and overall survival
Number of subjects: 40
Study: 31895257

Group type: EXPERIMENTAL
Intervention: Vibratory anesthetic device (VAD ON)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (VAD OFF)
Number of subjects: 87
Study: 30293771

Group type: EXPERIMENTAL
Intervention: Lorcaserin (10 mg twice daily)
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12000
Study: 28495264

Group type: COMPARATOR
Intervention: Routine polio programme activities (Control, arm A)
Number of subjects: 28784

Group type: EXPERIMENTAL
Intervention: Additional interventions with community outreach and mobilisation (arm B)
Number of subjects: 28784

Group type: EXPERIMENTAL
Intervention: All interventions of arm B with additional provision of IPV (arm C)
Number of subjects: 28784
Study: 26402941

Group type: EXPERIMENTAL
Intervention: Enteral oxygen therapy (oxygen smoothies based on protein-carbohydrate raw materials with dietary fiber), 500 ml daily for 10 days.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Enteral oxygen therapy (oxygen smoothies)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aerated non-oxygen mixture (placebo)
Number of subjects: 60
Study: 22983681

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural stress management
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 21181639

Group type: EXPERIMENTAL
Intervention: Non-weight bearing (NWB) gastrocnemius stretching
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Weight bearing (WB) gastrocnemius stretching
Number of subjects: 28
Study: 18805509

Group type: EXPERIMENTAL
Intervention: Twice daily (BID) call schedule
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Once daily (OD) call schedule
Number of subjects: 71

Group type: COMPARATOR
Intervention: Three times daily (TID) call schedule
Number of subjects: 71
Study: 17144555

Group type: EXPERIMENTAL
Intervention: Combined treatment including physical factors (ultrasound, sinusoidal modulated currents‐‐SMC) and medicinal suppositories (diklofenak, vitaprost, polyoxidonium)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Combined administration of physical factors and medicinal suppositories
Number of subjects: 112
Study: 14520685

Group type: EXPERIMENTAL
Intervention: Narapril (Julphar, UAE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Renitec (MSD, Netherlands)
Number of subjects: 24
Study: 11147908

Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine administration
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 8790517

Group type: EXPERIMENTAL
Intervention: Inclusion of a standard, photocopied letter signed by the non-attender's doctor with the second invitation to attend for breast screening.
Number of subjects: 465

Group type: COMPARATOR
Intervention: Standard invitation from the breast screening centre (Control group).
Number of subjects: 465
Study: 3056255

Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 67

Group type: COMPARATOR
Intervention: Ampicillin-tobramycin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 67
Study: 31306290

Group type: EXPERIMENTAL
Intervention: Johns Hopkins RAPID‐PFA model
Number of subjects: 119

Group type: COMPARATOR
Intervention: Group conversation condition
Number of subjects: 119
Study: 28472933

Group type: EXPERIMENTAL
Intervention: Imagery rescripting (ImRs)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Eye movement desensitisation and reprocessing (EMDR)
Number of subjects: 142
Study: 25947010

Group type: EXPERIMENTAL
Intervention: Outpatient training (n=13)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard care (n=8)
Number of subjects: 21
Study: 23435496

Group type: EXPERIMENTAL
Intervention: Gender-same face pairings (two male faces or two female faces)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender-different face pairings (a male face preceded or followed by a female face)
Number of subjects: 0
Study: 21243371

Group type: EXPERIMENTAL
Intervention: Octopus 3°/second
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Octopus 10°/second
Number of subjects: 40

Group type: COMPARATOR
Intervention: Goldmann
Number of subjects: 40

Group type: COMPARATOR
Intervention: Octopus 3°/second vs Goldmann
Number of subjects: 40

Group type: COMPARATOR
Intervention: Octopus 10°/second vs Goldmann
Number of subjects: 40

Group type: COMPARATOR
Intervention: Octopus 3°/second vs Goldmann (patient group)
Number of subjects: 40
Study: 19411798

Group type: EXPERIMENTAL
Intervention: RLG (rocuronium 0.6 mg/kg mixed with 2 mL of 2% lidocaine)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: RSG (rocuronium 0.6 mg/kg with 8.4% sodium bicarbonate)
Number of subjects: 75

Group type: COMPARATOR
Intervention: RG (rocuronium 0.6 mg/kg)
Number of subjects: 75